Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer

Author(s): Paul Brittain, S. Gail Eckhardt and Christopher H. Lieu

Volume 10, Issue 1, 2014

Page: [34 - 38] Pages: 5

DOI: 10.2174/157339471001140815152055

Price: $65

Abstract

The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogenesis of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including potential rational combination strategies and the investigation into potential predictive biomarkers of response.

Keywords: Colorectal Cancer, MAPK Pathway, MEK Inhibitor, Targeted Therapy.


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy